Topical pimecrolimus 1 cream for resistant seborrheic dermatitis of the face: An open-label study

American Journal of Clinical Dermatology

Volumn 11, Issue 1, 2010, Pages 51-54

  Ozden, Muge Guler ^a   Tekin, Nilgun Solak ^b   Lter, Nilsel ^c   Ankarali, Handan ^b  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PIMECROLIMUS;

ADULT; AGED; ARTICLE; BLISTER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DRUG EFFICACY; ERYTHEMA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PRURITUS; SCORING SYSTEM; SEBORRHEIC DERMATITIS; SKIN ATROPHY; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; DERMATITIS, SEBORRHEIC; DERMATOLOGIC AGENTS; FACE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; RETROSPECTIVE STUDIES; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949350050     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11311160-000000000-00000     Document Type: Article

References (17)

1. Gupta AK, Bluhm R, Cooper EA, et al. Seborrheic dermatitis. Dermatol Clin 2003; 21: 401-412
2. Zaidi Z, Wahid Z, Cochinwala R, et al. Correlation of the density of yeast Malassezia with the clinical severity of seborrheic dermatitis. J Pak Med Assoc 2002; 52: 504-506
3. Meingassner JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 508-576
4. Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009; 124: 19-28
5. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264-273
6. Kalthoff FS, Chung J, Musser P, et al. Pimecrolimus does not affect the dif-ferentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003 Sep; 133 (3): 350-359
7. Meurer M, Folster-Holst R, Wozel G, et al.; CASM-DE-01 study group. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271-277
8. Rallis E, Nasiopoulou A, Kouskoukis C, et al. Pimecrolimus cream 1% can be effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res 2004; 30: 191-195
9. Rigopoulos D, Ioannides D, Kalogeromitros D, et al. Pimecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis: arandomized open-label clinical trial.Br J Dermatol 2004; 151: 1071-1075
10. Cicek D, Kandi B, Bakar S, et al. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of se-borrhoeic dermatitis: a randomized clinical study. J Dermatolog Treat. Epub 2009 Jan 1
11. Tatlican S, Eren C, Oktay B, et al. Experience with repetitive use of pimecro-limus: exploring the effective and safe use in the treatment of relapsing se-borrheic dermatitis. J Dermatolog Treat. Epub 2009 Jan 1
12. Cunha PR. Pimecrolimus cream 1% is effective in seborrhoeic dermatitis re-fractory to treatment with topical corticosteroids. Acta Derm Venereol 2006; 86: 69-70
13. Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007; 57: 257-264
14. Langley RG, Eichenfield LF, Lucky AW, et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol 2008 May-Jun; 25 (3): 301-307
15. Mrowietz U, Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-996
16. Firooz A, SolhpourA, Gorouhi F,et al. Pimecrolimus cream, 1%, vshydrocor-tisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006; 142: 1066-1067
17. Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J 2003; 9: 13